Ketamine IV vs Nasal: Which Is Right for You?

You've decided ketamine might be worth trying. Now you're stuck on a different question: should it go in your arm or up your nose? The studies seem to disagree, and the choice affects your time, your wallet, and how you'll feel during treatment. It's a genuinely confusing place to be.

The short answer: the two are roughly comparable on how well they work, so the choice usually comes down to speed, cost, and insurance. IV ketamine pulls ahead in the first session or two and lets clinicians fine-tune the dose, but it runs $400 to $800 per session and insurance rarely covers it.

Nasal esketamine (Spravato) has a higher retail price, often $600 to $1,500 a session, but because it is FDA-approved, insurance frequently covers it. That makes it the cheaper, more practical option for most people.

The quick rule: choose IV if you need the fastest relief or flexible dosing and can pay cash; choose Spravato if cost and coverage matter most. There's also a third path, covered below: clinically supervised at-home ketamine, which skips the clinic entirely and costs far less than either.

What Is IV Ketamine?

IV ketamine is racemic ketamine dripped into a vein over about 40 minutes. Racemic means it contains both mirror-image forms of the molecule in equal parts. Because it goes directly into your bloodstream, nearly all of it reaches circulation, roughly 100% bioavailability, and the dose is set by your body weight, so it can be tailored to you.

For depression and anxiety, it's used off-label: the FDA approved ketamine only as an anesthetic, and that status shapes how insurance treats it.

What Is Nasal Esketamine (Spravato)?

Spravato is a nasal spray containing only one form of ketamine, the S form, which is more potent on its own. You absorb it through the lining of your nose, and compared with IV, less reaches your bloodstream, roughly 48 to 54%, an amount that varies if some spray is swallowed or if congestion affects absorption.

It uses fixed doses rather than weight-based dosing. Approved for treatment-resistant depression (TRD) in 2019, it became the first monotherapy approved for TRD in January 2025, and it carries a mandatory safety program because of sedation, dissociation, and misuse potential.

How Well and How Fast Each One Works

Both treatments work through related ketamine mechanisms, like clearing fresh paths through an overgrown forest. The difference is how the medication arrives, and that shapes how fast it works. With IV, ketamine reaches your brain quickly and the dose is precise, so your clinician can watch your response in real time; a single infusion can produce effects within about 40 minutes to 2 hours, far faster than traditional antidepressants, and those effects tend to peak around 24 hours.

Nasal esketamine arrives more slowly, building over 20 to 40 minutes after the last spray, with meaningful improvement usually within 24 hours of the first dose, and that slower, lower absorption tends to produce a milder peak.

The clearest head-to-head picture comes from a 2025 retrospective study of 153 adults with severe TRD at McLean Hospital. IV patients improved significantly after just the first session, while esketamine patients needed two.

The size of the effect followed suit: over the induction period, the IV group saw a 49% reduction in depression scores versus about 40% for esketamine. When you're in real distress and counting the days, getting relief a session or two sooner can matter more than it looks like on paper.

How Long Relief Lasts

A single dose of either is temporary, lasting from a few days to about two weeks. IV relief usually holds 3 to 7 days, though Mayo Clinic cites 10 to 12 days; a single esketamine dose fades within about a week. The full course matters more: one comparative study put mean duration at 13.8 days for IV versus 8.4 days for nasal, though that nasal figure is a single data point.

Esketamine's clearer edge is staying power over time. It has more long-term long-term data and showed a 51% drop in relapse among people who reached stable remission and kept using it as ongoing support.

Side Effects and the Treatment Experience

Both routes share a similar side effect profile (dissociation, sedation, nausea, dizziness, and temporary blood pressure increases), but the experience differs. IV delivers a faster, more intense peak because the dose hits all at once, though the dissociation usually fades within two hours and tends not to worsen across sessions.

Nasal esketamine generally produces milder acute effects, but adds nasal-specific ones: nasal irritation, a runny nose, and an unpleasant taste. In Spravato's trials, dissociation occurred in about 31% of people and generally resolved the same day. With either route, knowing roughly what it feels like ahead of time makes the dissociation easier to sit with.

Spravato carries FDA boxed warnings for sedation, dissociation, respiratory depression, misuse, and suicidal thoughts. Both treatments temporarily impair judgment and reaction time, so you'll need a ride home and can't drive until you've had a full night of sleep.

Cost and Insurance: The Real Deciding Factor

For most people, cost and insurance settle this more than any clinical finding. IV ketamine runs $400 to $800 per session, and because psychiatric use is off-label, insurance almost never covers it, so a full induction series can climb into the thousands, all on you. Spravato has the higher sticker price, often $600 to $1,500 per session, but FDA approval makes coverage far more likely, usually after prior authorization showing two antidepressants haven't worked, which can delay your start by weeks.

Even with insurance, Spravato often still runs $600 to $900 a session, and partial coverage can leave large balances unless you qualify for the manufacturer's patient-assistance program.

Here's the part that sounds backwards at first. Per unit of clinical benefit, IV is often the cheaper treatment, since one observational analysis found reaching the same improvement cost several times more with esketamine.

But that only helps if you can pay cash. Because insurers rarely cover off-label IV, the practical reality flips: esketamine usually costs you less out of pocket when coverage applies, even though it costs the system more.

IV, Nasal, and Innerwell: Side by Side

Which One Might Fit You

No well-powered head-to-head randomized trial has been published yet. The big one, the Yale-led EQUIVALENCE trial of 400 people, is the first designed to settle it. Until then, most direct comparisons come from observational data, and a meta-analysis of 11 studies found no statistically significant efficacy difference between the routes, so any claim that one is clearly better deserves a measured read.

Still, a few situations point one way or the other:

• IV ketamine may make more sense if you have bipolar depression, since IV has supporting evidence and esketamine has no published studies for it. Its weight-based dosing offers flexibility, and the longer gap between maintenance sessions, about 18.9 days versus roughly 10.8 for Spravato, means fewer visits over time.
• Nasal esketamine may make more sense if cost and insurance are real constraints, which they are for most people. It also has FDA approval, more long-term safety data, and a specific approval for major depressive disorder (MDD) with acute suicidal ideation, where it produced a rapid drop in depressive symptoms within hours of the first dose.

Some situations rule out both routes for now, including uncontrolled high blood pressure or certain vascular conditions, active psychosis, and pregnancy. If any of those apply to you, it doesn't mean you're out of options, just that ketamine isn't the safe next step right now. A thorough screening is how a good care team sorts this out with you honestly.

What About Nasal Ketamine You Can Use at Home?

A lot of people searching for a nasal option are really after one thing: ketamine without the clinic. But the cheap at-home sprays advertised online aren't Spravato, which can't be used at home and must be given in a certified facility under observation.

The low-cost sprays marketed for home use are compounded ketamine, mixed by a pharmacy rather than FDA-approved, and the FDA has issued a safety warning about them.

The danger here comes from the missing structure around these sprays, not the nasal route itself. Compounded sprays often reach people with little screening, inconsistent dosing, and no one on hand if something goes wrong. Cheaper upfront can quietly mean less safe.

There is a middle path, though, one that keeps the convenience of treating at home without giving up clinical oversight, and it's what Innerwell is built around.

How Innerwell's At-Home Ketamine Therapy Works

That middle path uses sublingual tablets you take at home, with licensed clinical support around every session and no clinic hours or travel. Rather than handing you medication and leaving you to it, the program pairs the ketamine with clinical oversight, preparation, and integration therapy, the part that helps you actually use what the treatment opens up.

The process:

1. Evaluation: A licensed clinician reviews your history, symptoms, medications, and goals to confirm ketamine therapy is a safe fit.
2. Delivery: Sublingual tablets ship to your home through a licensed pharmacy, with clear dosing guidance.
3. Preparation and integration: Master's and Doctoral level therapists help you prepare beforehand and process what surfaces afterward. The medication opens a door; integration therapy helps you walk through it.
4. Ongoing monitoring: The platform tracks your mood and progress while your care team reviews feedback and adjusts your plan.

Through insurance partnerships, plans start as low as $54 per session with insurance, and self-pay runs $83 to $125, well below IV clinics or Spravato's retail price.

Based on Innerwell's own program data, people in the program have seen a 69% reduction in depression symptoms and a 60% reduction in anxiety symptoms after 10 weeks, with 87% improving within four weeks. The average patient rating is 4.7 out of 5.

Take the free assessment to see if ketamine therapy might be right for you.

Frequently Asked Questions

Can I switch from one to the other later?

Yes, and some people do. A common pattern is starting with IV for faster early relief, then moving to Spravato for insurance-covered maintenance once stable. A small case series of people who switched from IV to Spravato mostly held or improved their gains. The reverse happens too, when someone wants weight-based dosing or a stronger response. The dose isn't a simple one-to-one conversion, so any switch should be planned with your prescriber.

How much time does each session take?

Plan on about two hours either way. IV ketamine is a 40 to 60 minute infusion plus recovery, and Spravato requires two hours of in-facility monitoring after dosing. That's part of why an at-home option appeals to people whose schedules can't absorb repeated half-day clinic visits.

Can insurance ever cover IV ketamine?

Rarely, and not reliably. Because IV ketamine is used off-label for depression, most plans won't pay for the infusion itself, though some people get partial reimbursement for associated costs like the office visit. Spravato's FDA approval is what makes its coverage far more routine. If predictable cost matters most, that gap is usually the deciding factor.